Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials

The recepteur d’origine nantais (RON) receptor tyrosine kinase, belonging to the mesenchymal-to-epithelial transition proto-oncogene family, has been implicated in the pathogenesis of cancers derived from the colon, lung, breast, and pancreas. These findings lay the foundation for targeting RON for...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Hang-Ping, Suthe, Sreedhar Reddy, Tong, Xiang-Min, Wang, Ming-Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222236/
https://www.ncbi.nlm.nih.gov/pubmed/32426050
http://dx.doi.org/10.1177/1758835920920069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222236/
https://www.ncbi.nlm.nih.gov/pubmed/32426050
http://dx.doi.org/10.1177/1758835920920069

Ejemplares similares